Trevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a report issued on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and issued a $5.00 target price on shares of Trevena in a research note on Thursday, November 14th.

Trevena Stock Down 11.5 %

Shares of Trevena stock opened at $1.50 on Friday. Trevena has a 52 week low of $1.13 and a 52 week high of $19.23. The firm’s 50 day moving average is $1.75 and its two-hundred day moving average is $3.72. The firm has a market capitalization of $1.29 million, a P/E ratio of -0.03 and a beta of 1.08.

Trevena (NASDAQ:TRVN) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The company had revenue of $0.28 million for the quarter. As a group, research analysts expect that Trevena will post -23.04 earnings per share for the current fiscal year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.